Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | ABL1 G321L |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02029001 | Phase II | Durvalumab + Tremelimumab Olaparib Pazopanib Nilotinib | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment (MOST plus) | Recruiting | FRA | 0 |
NCT01593254 | Phase II | Imatinib Dasatinib | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN) | Completed | USA | ITA | FRA | ESP | CAN | BEL | AUT | 8 |
NCT01744665 | Phase II | Nilotinib | Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5. (ENESTgoal) | Completed | USA | 0 |
NCT04925479 | Phase Ib/II | Asciminib | Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | Recruiting | USA | ITA | FRA | DEU | 7 |
NCT04329325 | Phase II | Dasatinib + Dexamethasone + Methotrexate Blinatumomab + Dasatinib + Methotrexate | Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT03106779 | Phase III | Bosutinib Asciminib | Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 19 |
NCT04793399 | Phase Ib/II | Atezolizumab + Bosutinib | Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients | Recruiting | ESP | 0 |
NCT03874858 | Phase II | Nilotinib | A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia Treated With Nilotinib (DANTE) | Recruiting | ITA | 0 |
NCT02311998 | Phase Ib/II | Bosutinib + Inotuzumab ozogamicin | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | Completed | USA | 0 |
NCT02228382 | FDA approved | Bosutinib | Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors | Terminated | USA | ITA | FRA | ESP | DEU | AUT | 2 |
NCT02782403 | Phase Ib/II | Axitinib + Bosutinib | Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia | Terminated | USA | 0 |
NCT02081378 | Phase I | Asciminib Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib | A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 5 |
NCT04835584 | Phase Ib/II | Dasatinib + KRT-232 KRT-232 + Nilotinib | KRT-232 and TKI Study in Chronic Myeloid Leukemia | Recruiting | USA | ITA | FRA | ESP | CAN | 3 |
NCT02629692 | Phase Ib/II | K0706 | Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant CML Failing >/=3 Prior CML Therapies | Recruiting | USA | ITA | FRA | ESP | BEL | 6 |
NCT02538926 | Phase II | Imatinib Rituximab Cyclophosphamide Prednisone Doxorubicin + Etoposide + Vincristine Sulfate Asparaginase | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Withdrawn | USA | 0 |
NCT04160546 | Phase II | Aspirin + Ponatinib | Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) | Recruiting | ESP | 0 |
NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | Recruiting | CAN | 0 |
NCT03375307 | Phase II | Olaparib | Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer With DNA-Repair Genetic Changes | Recruiting | USA | 0 |
NCT02767063 | Phase Ib/II | Avelumab Pioglitazone | Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) | Recruiting | FRA | 0 |
NCT02730195 | Phase II | Pioglitazone | Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia | Terminated | USA | 0 |
NCT04501614 | Phase Ib/II | Ponatinib | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Recruiting | USA | ITA | FRA | ESP | 11 |
NCT02272998 | Phase II | Ponatinib | Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. | Unknown status | USA | 0 |